MOTS-c Side Effects: A Mitochondrial Peptide Not Approved for Human Use
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, identified by Lee and colleagues in 2015. It has been studied in cell and animal models for effects on metabolism, insulin sensitivity, and exercise. It is not FDA- or TGA-approved for any human therapeutic use. WADA prohibits it. Human safety data are very limited.
MOTS-c is not FDA-approved and lacks controlled human safety data. Not FDA- or TGA-approved. Mostly studied in cell culture and animals. WADA prohibits competitive use. No long-term human safety data. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- MOTS-c is a mitochondrial-derived peptide identified in 2015. Not FDA-approved. Not TGA-approved.
- Marketed for metabolic and exercise-related uses without controlled human safety data.
- Most published evidence is from cell culture and animal models of diet-induced obesity, not human clinical trials.
- WADA prohibits MOTS-c in competitive sport.
- Compounded or research-grade product is not pharmaceutical-grade and has not been characterised for human use.
What is MOTS-c, and what is it marketed for?
MOTS-c (mitochondrial-derived peptide). MOTS-c is encoded within the mitochondrial 12S rRNA region. Published research describes effects on metabolic homeostasis, including AMPK pathway activation, improved insulin sensitivity in animal models of diet-induced obesity, and exercise-related signalling. Mechanisms in humans are not well characterised.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Hypoglycaemia signal in animal studies | Animal model studies suggest insulin-sensitising effects, which could theoretically affect blood glucose in humans | Animal data only |
| Injection-site infection | Pain, warmth, swelling, abscess | Non-sterile injection of research-grade product |
| Impurity exposure | Variable purity and potency in gray-market product | No pharmaceutical-grade product exists |
| WADA prohibited | Listed under WADA prohibited substances | Section S2 |
| Long-term safety | No long-term human safety studies | All current evidence is preclinical or very early human |
Taking MOTS-c alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About MOTS-c
No. MOTS-c is not approved by the FDA or TGA for any human therapeutic use.
Published research, much of it from the laboratory of Pinchas Cohen and colleagues, describes a mitochondrial-derived peptide that influences AMPK signalling and insulin sensitivity in animal models. Human clinical safety and efficacy data are very limited.
Safety has not been established in controlled human trials. The combination of limited human data, lack of pharmaceutical-grade product, and the unknowns of injecting compounded peptides means that safety claims cannot be supported by regulator review.
Yes. WADA prohibits MOTS-c.
References
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. Source.
- Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.